Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis: An open multicenter study

Seung Ju Lee, Su Jin Kim, Yong Hyun Cho, Young Nam Woo, Bup Wan Kim, Sung Goo Chang, Min Eui Kim, Chul Sung Kim, Jeong Gu Lee, Bong Suck Sim, Hyung Jin Kim, Byung Ha Chung, In Rae Cho, Sang Don Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: We wanted to investigate the efficacy and safety of the immunotherapeutic Uro-Vaxom for treating uncomplicated recurrent cystitis in female patients only. Materials and Methods: Adult female patients were enrolled in this multicenter, open-label study if they had acute cystitis at the enrollment visit and positive results on urine culture (≥103 CFU/ml). The patients were treated for 3 months with one capsule daily of Uro-Vaxom after antibiotic therapy, and they were observed for another 3 months. The primary efficacy criteria were the cystitis recurrence rates over 6 months, the distribution of cystitis and the proportion of patients with cystitis. Results: A total of 50 patients were evaluated. During the 6-month trial, the number of cystitis recurrences was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, respectively p < 0.001). The incidences of frequency, urgency and dysuria remained low until the end of the trial. Uro-Vaxom was well tolerated: side-effects were mentioned by 8% of the 50 patients, and there was no case leading to treatment withdrawal. Conclusions: Uro-Vaxom significantly reduced the incidence of cystitis during the 6 months of this study, including the 3 months of treatment. These results demonstrate that Uro-Vaxom is a valuable agent for prophylaxis of recurrent cystitis.

Original languageEnglish
Pages (from-to)428-432
Number of pages5
JournalKorean Journal of Urology
Volume48
Issue number4
Publication statusPublished - 2007 Apr 1

Fingerprint

Cystitis
Multicenter Studies
Safety
Therapeutics
Recurrence
Dysuria
OM-8930
Incidence
Capsules
Urine
Anti-Bacterial Agents

Keywords

  • Cystitis
  • Escherichia coli
  • Female
  • Uro-Vaxom

ASJC Scopus subject areas

  • Urology

Cite this

Lee, S. J., Kim, S. J., Cho, Y. H., Woo, Y. N., Kim, B. W., Chang, S. G., ... Lee, S. D. (2007). Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis: An open multicenter study. Korean Journal of Urology, 48(4), 428-432.

Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis : An open multicenter study. / Lee, Seung Ju; Kim, Su Jin; Cho, Yong Hyun; Woo, Young Nam; Kim, Bup Wan; Chang, Sung Goo; Kim, Min Eui; Kim, Chul Sung; Lee, Jeong Gu; Sim, Bong Suck; Kim, Hyung Jin; Chung, Byung Ha; Cho, In Rae; Lee, Sang Don.

In: Korean Journal of Urology, Vol. 48, No. 4, 01.04.2007, p. 428-432.

Research output: Contribution to journalArticle

Lee, SJ, Kim, SJ, Cho, YH, Woo, YN, Kim, BW, Chang, SG, Kim, ME, Kim, CS, Lee, JG, Sim, BS, Kim, HJ, Chung, BH, Cho, IR & Lee, SD 2007, 'Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis: An open multicenter study', Korean Journal of Urology, vol. 48, no. 4, pp. 428-432.
Lee, Seung Ju ; Kim, Su Jin ; Cho, Yong Hyun ; Woo, Young Nam ; Kim, Bup Wan ; Chang, Sung Goo ; Kim, Min Eui ; Kim, Chul Sung ; Lee, Jeong Gu ; Sim, Bong Suck ; Kim, Hyung Jin ; Chung, Byung Ha ; Cho, In Rae ; Lee, Sang Don. / Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis : An open multicenter study. In: Korean Journal of Urology. 2007 ; Vol. 48, No. 4. pp. 428-432.
@article{c4df6206baa54b14bbde62423ef94393,
title = "Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis: An open multicenter study",
abstract = "Purpose: We wanted to investigate the efficacy and safety of the immunotherapeutic Uro-Vaxom for treating uncomplicated recurrent cystitis in female patients only. Materials and Methods: Adult female patients were enrolled in this multicenter, open-label study if they had acute cystitis at the enrollment visit and positive results on urine culture (≥103 CFU/ml). The patients were treated for 3 months with one capsule daily of Uro-Vaxom after antibiotic therapy, and they were observed for another 3 months. The primary efficacy criteria were the cystitis recurrence rates over 6 months, the distribution of cystitis and the proportion of patients with cystitis. Results: A total of 50 patients were evaluated. During the 6-month trial, the number of cystitis recurrences was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, respectively p < 0.001). The incidences of frequency, urgency and dysuria remained low until the end of the trial. Uro-Vaxom was well tolerated: side-effects were mentioned by 8{\%} of the 50 patients, and there was no case leading to treatment withdrawal. Conclusions: Uro-Vaxom significantly reduced the incidence of cystitis during the 6 months of this study, including the 3 months of treatment. These results demonstrate that Uro-Vaxom is a valuable agent for prophylaxis of recurrent cystitis.",
keywords = "Cystitis, Escherichia coli, Female, Uro-Vaxom",
author = "Lee, {Seung Ju} and Kim, {Su Jin} and Cho, {Yong Hyun} and Woo, {Young Nam} and Kim, {Bup Wan} and Chang, {Sung Goo} and Kim, {Min Eui} and Kim, {Chul Sung} and Lee, {Jeong Gu} and Sim, {Bong Suck} and Kim, {Hyung Jin} and Chung, {Byung Ha} and Cho, {In Rae} and Lee, {Sang Don}",
year = "2007",
month = "4",
day = "1",
language = "English",
volume = "48",
pages = "428--432",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis

T2 - An open multicenter study

AU - Lee, Seung Ju

AU - Kim, Su Jin

AU - Cho, Yong Hyun

AU - Woo, Young Nam

AU - Kim, Bup Wan

AU - Chang, Sung Goo

AU - Kim, Min Eui

AU - Kim, Chul Sung

AU - Lee, Jeong Gu

AU - Sim, Bong Suck

AU - Kim, Hyung Jin

AU - Chung, Byung Ha

AU - Cho, In Rae

AU - Lee, Sang Don

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Purpose: We wanted to investigate the efficacy and safety of the immunotherapeutic Uro-Vaxom for treating uncomplicated recurrent cystitis in female patients only. Materials and Methods: Adult female patients were enrolled in this multicenter, open-label study if they had acute cystitis at the enrollment visit and positive results on urine culture (≥103 CFU/ml). The patients were treated for 3 months with one capsule daily of Uro-Vaxom after antibiotic therapy, and they were observed for another 3 months. The primary efficacy criteria were the cystitis recurrence rates over 6 months, the distribution of cystitis and the proportion of patients with cystitis. Results: A total of 50 patients were evaluated. During the 6-month trial, the number of cystitis recurrences was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, respectively p < 0.001). The incidences of frequency, urgency and dysuria remained low until the end of the trial. Uro-Vaxom was well tolerated: side-effects were mentioned by 8% of the 50 patients, and there was no case leading to treatment withdrawal. Conclusions: Uro-Vaxom significantly reduced the incidence of cystitis during the 6 months of this study, including the 3 months of treatment. These results demonstrate that Uro-Vaxom is a valuable agent for prophylaxis of recurrent cystitis.

AB - Purpose: We wanted to investigate the efficacy and safety of the immunotherapeutic Uro-Vaxom for treating uncomplicated recurrent cystitis in female patients only. Materials and Methods: Adult female patients were enrolled in this multicenter, open-label study if they had acute cystitis at the enrollment visit and positive results on urine culture (≥103 CFU/ml). The patients were treated for 3 months with one capsule daily of Uro-Vaxom after antibiotic therapy, and they were observed for another 3 months. The primary efficacy criteria were the cystitis recurrence rates over 6 months, the distribution of cystitis and the proportion of patients with cystitis. Results: A total of 50 patients were evaluated. During the 6-month trial, the number of cystitis recurrences was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, respectively p < 0.001). The incidences of frequency, urgency and dysuria remained low until the end of the trial. Uro-Vaxom was well tolerated: side-effects were mentioned by 8% of the 50 patients, and there was no case leading to treatment withdrawal. Conclusions: Uro-Vaxom significantly reduced the incidence of cystitis during the 6 months of this study, including the 3 months of treatment. These results demonstrate that Uro-Vaxom is a valuable agent for prophylaxis of recurrent cystitis.

KW - Cystitis

KW - Escherichia coli

KW - Female

KW - Uro-Vaxom

UR - http://www.scopus.com/inward/record.url?scp=34247882728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247882728&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34247882728

VL - 48

SP - 428

EP - 432

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 4

ER -